TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
15 août 2024 07h00 HE
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
TransCode Therapeutics, Inc. Announces Closing of Public Offering
24 juil. 2024 16h05 HE
|
TransCode Therapeutics, Inc.
Boston, MA — July 24, 2024 — TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed to
TransCode Therapeutics, Inc. Announces Pricing of Public Offering
22 juil. 2024 22h30 HE
|
TransCode Therapeutics, Inc.
Boston, MA — July 22, 2024 — TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed t
TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
22 juil. 2024 16h07 HE
|
TransCode Therapeutics, Inc.
Boston, MA – July 22, 2024 – TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed t
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
10 juin 2024 07h00 HE
|
TransCode Therapeutics, Inc.
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
29 mai 2024 09h15 HE
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
TransCode Therapeutics Open Letter to Shareholders
13 mai 2024 08h30 HE
|
TransCode Therapeutics, Inc.
An Open Letter to Shareholders regarding a Reverse Stock Split
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
15 avr. 2024 09h00 HE
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
TransCode Therapeutics Reports 2023 Results; Provides Business Update
03 avr. 2024 09h10 HE
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Reports 2023 Results; Provides Business Update
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
28 mars 2024 08h30 HE
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer